AR113258A1 - Conjugados persistentes de derivados del péptido 2 similar al glucagón (glp-2) - Google Patents
Conjugados persistentes de derivados del péptido 2 similar al glucagón (glp-2)Info
- Publication number
- AR113258A1 AR113258A1 ARP180102806A ARP180102806A AR113258A1 AR 113258 A1 AR113258 A1 AR 113258A1 AR P180102806 A ARP180102806 A AR P180102806A AR P180102806 A ARP180102806 A AR P180102806A AR 113258 A1 AR113258 A1 AR 113258A1
- Authority
- AR
- Argentina
- Prior art keywords
- glp
- glucagon
- peptide
- lysine
- derivative
- Prior art date
Links
- TWSALRJGPBVBQU-PKQQPRCHSA-N glucagon-like peptide 2 Chemical compound C([C@@H](C(=O)N[C@H](C(=O)N[C@@H](CC(N)=O)C(=O)N[C@@H](CC=1C2=CC=CC=C2NC=1)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H]([C@@H](C)CC)C(=O)N[C@@H](CCC(N)=O)C(=O)N[C@@H]([C@@H](C)O)C(=O)N[C@@H](CCCCN)C(=O)N[C@@H]([C@@H](C)CC)C(=O)N[C@@H]([C@@H](C)O)C(=O)N[C@@H](CC(O)=O)C(O)=O)[C@@H](C)CC)NC(=O)[C@H](CC(O)=O)NC(=O)[C@H](CCCNC(N)=N)NC(=O)[C@H](C)NC(=O)[C@H](C)NC(=O)[C@H](CC(C)C)NC(=O)[C@H](CC(N)=O)NC(=O)[C@H](CC(O)=O)NC(=O)[C@H](CC(C)C)NC(=O)[C@@H](NC(=O)[C@@H](NC(=O)[C@H](CC(N)=O)NC(=O)[C@H](CCSC)NC(=O)[C@H](CCC(O)=O)NC(=O)[C@H](CC(O)=O)NC(=O)[C@H](CO)NC(=O)[C@H](CC=1C=CC=CC=1)NC(=O)[C@H](CO)NC(=O)CNC(=O)[C@H](CC(O)=O)NC(=O)[C@H](C)NC(=O)[C@@H](N)CC=1NC=NC=1)[C@@H](C)O)[C@@H](C)CC)C1=CC=CC=C1 TWSALRJGPBVBQU-PKQQPRCHSA-N 0.000 title abstract 10
- 101800000221 Glucagon-like peptide 2 Proteins 0.000 title abstract 6
- 102000051325 Glucagon Human genes 0.000 title 1
- 108060003199 Glucagon Proteins 0.000 title 1
- 102400000326 Glucagon-like peptide 2 Human genes 0.000 title 1
- MASNOZXLGMXCHN-ZLPAWPGGSA-N glucagon Chemical compound C([C@@H](C(=O)N[C@H](C(=O)N[C@@H](CCC(N)=O)C(=O)N[C@@H](CC=1C2=CC=CC=C2NC=1)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CCSC)C(=O)N[C@@H](CC(N)=O)C(=O)N[C@@H]([C@@H](C)O)C(O)=O)C(C)C)NC(=O)[C@H](CC(O)=O)NC(=O)[C@H](CCC(N)=O)NC(=O)[C@H](C)NC(=O)[C@H](CCCNC(N)=N)NC(=O)[C@H](CCCNC(N)=N)NC(=O)[C@H](CO)NC(=O)[C@H](CC(O)=O)NC(=O)[C@H](CC(C)C)NC(=O)[C@H](CC=1C=CC(O)=CC=1)NC(=O)[C@H](CCCCN)NC(=O)[C@H](CO)NC(=O)[C@H](CC=1C=CC(O)=CC=1)NC(=O)[C@H](CC(O)=O)NC(=O)[C@H](CO)NC(=O)[C@@H](NC(=O)[C@H](CC=1C=CC=CC=1)NC(=O)[C@@H](NC(=O)CNC(=O)[C@H](CCC(N)=O)NC(=O)[C@H](CO)NC(=O)[C@@H](N)CC=1NC=NC=1)[C@@H](C)O)[C@@H](C)O)C1=CC=CC=C1 MASNOZXLGMXCHN-ZLPAWPGGSA-N 0.000 title 1
- 229960004666 glucagon Drugs 0.000 title 1
- 230000002085 persistent effect Effects 0.000 title 1
- 108090000765 processed proteins & peptides Proteins 0.000 title 1
- 102100040918 Pro-glucagon Human genes 0.000 abstract 5
- 229920000642 polymer Polymers 0.000 abstract 4
- 125000001151 peptidyl group Chemical group 0.000 abstract 3
- FUOOLUPWFVMBKG-UHFFFAOYSA-N 2-Aminoisobutyric acid Chemical compound CC(C)(N)C(O)=O FUOOLUPWFVMBKG-UHFFFAOYSA-N 0.000 abstract 2
- 239000004475 Arginine Substances 0.000 abstract 2
- RTZKZFJDLAIYFH-UHFFFAOYSA-N Diethyl ether Chemical compound CCOCC RTZKZFJDLAIYFH-UHFFFAOYSA-N 0.000 abstract 2
- DHMQDGOQFOQNFH-UHFFFAOYSA-N Glycine Chemical group NCC(O)=O DHMQDGOQFOQNFH-UHFFFAOYSA-N 0.000 abstract 2
- 239000004472 Lysine Substances 0.000 abstract 2
- KDXKERNSBIXSRK-UHFFFAOYSA-N Lysine Natural products NCCCCC(N)C(O)=O KDXKERNSBIXSRK-UHFFFAOYSA-N 0.000 abstract 2
- 150000001413 amino acids Chemical group 0.000 abstract 2
- ODKSFYDXXFIFQN-UHFFFAOYSA-N arginine Natural products OC(=O)C(N)CCCNC(N)=N ODKSFYDXXFIFQN-UHFFFAOYSA-N 0.000 abstract 2
- HNDVDQJCIGZPNO-UHFFFAOYSA-N histidine Natural products OC(=O)C(N)CC1=CN=CN1 HNDVDQJCIGZPNO-UHFFFAOYSA-N 0.000 abstract 2
- KIUKXJAPPMFGSW-DNGZLQJQSA-N (2S,3S,4S,5R,6R)-6-[(2S,3R,4R,5S,6R)-3-Acetamido-2-[(2S,3S,4R,5R,6R)-6-[(2R,3R,4R,5S,6R)-3-acetamido-2,5-dihydroxy-6-(hydroxymethyl)oxan-4-yl]oxy-2-carboxy-4,5-dihydroxyoxan-3-yl]oxy-5-hydroxy-6-(hydroxymethyl)oxan-4-yl]oxy-3,4,5-trihydroxyoxane-2-carboxylic acid Chemical compound CC(=O)N[C@H]1[C@H](O)O[C@H](CO)[C@@H](O)[C@@H]1O[C@H]1[C@H](O)[C@@H](O)[C@H](O[C@H]2[C@@H]([C@@H](O[C@H]3[C@@H]([C@@H](O)[C@H](O)[C@H](O3)C(O)=O)O)[C@H](O)[C@@H](CO)O2)NC(C)=O)[C@@H](C(O)=O)O1 KIUKXJAPPMFGSW-DNGZLQJQSA-N 0.000 abstract 1
- IMOBSLOLPCWZKQ-UHFFFAOYSA-N 2-(dimethylazaniumyl)-3-(1h-imidazol-5-yl)propanoate Chemical compound CN(C)C(C(O)=O)CC1=CN=CN1 IMOBSLOLPCWZKQ-UHFFFAOYSA-N 0.000 abstract 1
- 229920002101 Chitin Polymers 0.000 abstract 1
- 229920002307 Dextran Polymers 0.000 abstract 1
- 239000004471 Glycine Chemical group 0.000 abstract 1
- 108060003951 Immunoglobulin Proteins 0.000 abstract 1
- XUJNEKJLAYXESH-REOHCLBHSA-N L-Cysteine Chemical compound SC[C@H](N)C(O)=O XUJNEKJLAYXESH-REOHCLBHSA-N 0.000 abstract 1
- ODKSFYDXXFIFQN-BYPYZUCNSA-P L-argininium(2+) Chemical compound NC(=[NH2+])NCCC[C@H]([NH3+])C(O)=O ODKSFYDXXFIFQN-BYPYZUCNSA-P 0.000 abstract 1
- ZDXPYRJPNDTMRX-VKHMYHEASA-N L-glutamine Chemical compound OC(=O)[C@@H](N)CCC(N)=O ZDXPYRJPNDTMRX-VKHMYHEASA-N 0.000 abstract 1
- HNDVDQJCIGZPNO-YFKPBYRVSA-N L-histidine Chemical compound OC(=O)[C@@H](N)CC1=CN=CN1 HNDVDQJCIGZPNO-YFKPBYRVSA-N 0.000 abstract 1
- KDXKERNSBIXSRK-YFKPBYRVSA-N L-lysine Chemical compound NCCCC[C@H](N)C(O)=O KDXKERNSBIXSRK-YFKPBYRVSA-N 0.000 abstract 1
- 239000002202 Polyethylene glycol Substances 0.000 abstract 1
- 239000004372 Polyvinyl alcohol Substances 0.000 abstract 1
- QFLNJOIJUNDRFH-ROLXFIACSA-N [(5s)-1,5-diamino-5-carboxypentyl]-diazonioazanide Chemical compound [N-]=[N+]=NC(N)CCC[C@H](N)C(O)=O QFLNJOIJUNDRFH-ROLXFIACSA-N 0.000 abstract 1
- 235000004279 alanine Nutrition 0.000 abstract 1
- 125000003295 alanine group Chemical group N[C@@H](C)C(=O)* 0.000 abstract 1
- 229920001577 copolymer Polymers 0.000 abstract 1
- 235000018417 cysteine Nutrition 0.000 abstract 1
- XUJNEKJLAYXESH-UHFFFAOYSA-N cysteine Natural products SCC(N)C(O)=O XUJNEKJLAYXESH-UHFFFAOYSA-N 0.000 abstract 1
- ZCKYOWGFRHAZIQ-UHFFFAOYSA-N dihydrourocanic acid Chemical compound OC(=O)CCC1=CNC=N1 ZCKYOWGFRHAZIQ-UHFFFAOYSA-N 0.000 abstract 1
- ZDXPYRJPNDTMRX-UHFFFAOYSA-N glutamine Natural products OC(=O)C(N)CCC(N)=O ZDXPYRJPNDTMRX-UHFFFAOYSA-N 0.000 abstract 1
- 150000004676 glycans Chemical class 0.000 abstract 1
- 125000000487 histidyl group Chemical group [H]N([H])C(C(=O)O*)C([H])([H])C1=C([H])N([H])C([H])=N1 0.000 abstract 1
- 229920002674 hyaluronan Polymers 0.000 abstract 1
- 229960003160 hyaluronic acid Drugs 0.000 abstract 1
- 102000018358 immunoglobulin Human genes 0.000 abstract 1
- FZWBNHMXJMCXLU-BLAUPYHCSA-N isomaltotriose Chemical compound O[C@@H]1[C@@H](O)[C@H](O)[C@@H](CO)O[C@@H]1OC[C@@H]1[C@@H](O)[C@H](O)[C@@H](O)[C@@H](OC[C@@H](O)[C@@H](O)[C@H](O)[C@@H](O)C=O)O1 FZWBNHMXJMCXLU-BLAUPYHCSA-N 0.000 abstract 1
- 150000002632 lipids Chemical class 0.000 abstract 1
- 238000004519 manufacturing process Methods 0.000 abstract 1
- 229920001583 poly(oxyethylated polyols) Polymers 0.000 abstract 1
- 229920001223 polyethylene glycol Polymers 0.000 abstract 1
- 229920001451 polypropylene glycol Polymers 0.000 abstract 1
- 229920001282 polysaccharide Polymers 0.000 abstract 1
- 239000005017 polysaccharide Substances 0.000 abstract 1
- 229920002451 polyvinyl alcohol Polymers 0.000 abstract 1
- 229920002554 vinyl polymer Polymers 0.000 abstract 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- C07K14/575—Hormones
- C07K14/605—Glucagons
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
- A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
- A61K47/62—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being a protein, peptide or polyamino acid
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
- A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
- A61K47/68—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
- C07K2317/52—Constant or Fc region; Isotype
- C07K2317/53—Hinge
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2319/00—Fusion polypeptide
- C07K2319/30—Non-immunoglobulin-derived peptide or protein having an immunoglobulin constant or Fc region, or a fragment thereof, attached thereto
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Organic Chemistry (AREA)
- General Health & Medical Sciences (AREA)
- Medicinal Chemistry (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Gastroenterology & Hepatology (AREA)
- Zoology (AREA)
- Biochemistry (AREA)
- Biophysics (AREA)
- Toxicology (AREA)
- Genetics & Genomics (AREA)
- Molecular Biology (AREA)
- Endocrinology (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Engineering & Computer Science (AREA)
- Pharmacology & Pharmacy (AREA)
- Animal Behavior & Ethology (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Epidemiology (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Immunology (AREA)
- Peptides Or Proteins (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Preparation Of Compounds By Using Micro-Organisms (AREA)
- Micro-Organisms Or Cultivation Processes Thereof (AREA)
- Medicinal Preparation (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
Abstract
La presente se refiere a derivados del péptido 2 similar al glucagón (GLP-2), sus conjugados y su uso. La presente también se refiere a un método para producir un derivado del péptido 2 similar al glucagón (GLP-2) y un conjugado del mismo. Reivindicación 1: Un conjugado de péptido tipo glucagón 2 (GLP-2), en el que un derivado de GLP-2 y una región Fc de inmunoglobulina están cada uno unidos de modo covalente por medio de un polímero no peptidilo en ambos extremos terminales del polímero no peptidilo, en el que el polímero no peptidilo se selecciona del grupo que consiste en polietilenglicol, polipropilenglicol, copolímero de etilenglicol-propilenglicol, poliol polioxietilado, alcohol polivinílico, polisacárido, dextrano, polivinil etil éter, polímero lipídico, quitina, ácido hialurónico y una combinación de los mismos. Reivindicación 2: El conjugado de GLP-2 de acuerdo con la reivindicación 1, en el que el derivado de GLP-2 comprende una secuencia de aminoácidos de la siguiente fórmula general (1): X¹X²DGSFSDEMNTILDNLAARDFlNWLlQTX³⁰ITDX³⁴ (SEQ ID Nº 9) (1), en el que la formula anterior, X¹ es histidina, imidazoacetildeshistidina, desaminohistidina, b-hidroxiimidazopropionildeshistidina, N-dimetilhistidina. o b-carboxiimidazopropionildeshistidina; X² es alanina, glicina, o ácido 2-aminoisobutírico (Aib); X³⁰ es lisina o arginina; X³⁴ está ausente, o lisina, arginina, glutamina, histidina, 6-azido-lisina, o cisteína; con la condición de que se excluya cualquier secuencia idéntica a una secuencia dé aminoácidos dé la SEQ ID Nº 1 en la fórmula general (1).
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| KR20170126577 | 2017-09-28 |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| AR113258A1 true AR113258A1 (es) | 2020-03-11 |
Family
ID=65902619
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| ARP180102806A AR113258A1 (es) | 2017-09-28 | 2018-09-28 | Conjugados persistentes de derivados del péptido 2 similar al glucagón (glp-2) |
Country Status (16)
| Country | Link |
|---|---|
| US (3) | US11530249B2 (es) |
| EP (1) | EP3689898A4 (es) |
| JP (2) | JP2020534840A (es) |
| CN (1) | CN111433221A (es) |
| AR (1) | AR113258A1 (es) |
| AU (1) | AU2018339210B2 (es) |
| BR (1) | BR112020006189A2 (es) |
| CA (1) | CA3084326A1 (es) |
| EA (1) | EA202090571A1 (es) |
| IL (1) | IL273528A (es) |
| MX (1) | MX2020004453A (es) |
| PH (1) | PH12020550105A1 (es) |
| SG (1) | SG11202002563WA (es) |
| TW (2) | TWI795443B (es) |
| WO (1) | WO2019066586A1 (es) |
| ZA (1) | ZA202001888B (es) |
Families Citing this family (4)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| KR20210082120A (ko) * | 2019-12-24 | 2021-07-02 | 한미약품 주식회사 | Glp-2 또는 이의 결합체를 포함하는 골 대사성 질환에 대한 예방 또는 치료용 약학적 조성물 |
| US20230110689A1 (en) | 2020-03-30 | 2023-04-13 | Zealand Pharma A/S | Agonist combination |
| US20230159607A1 (en) * | 2020-04-03 | 2023-05-25 | Hanmi Pharm. Co., Ltd. | Pharmaceutical composition for preventing or treating mucositis induced by radiotherapy, chemotherapy, or combination thereof, comprising glp-2 derivatives or long-acting conjugate of same |
| BR112022025141A2 (pt) | 2020-06-09 | 2023-04-25 | Vectivbio Ag | Fabricação, formulação e dosagem de apraglutida |
Family Cites Families (11)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US6096871A (en) | 1995-04-14 | 2000-08-01 | Genentech, Inc. | Polypeptides altered to contain an epitope from the Fc region of an IgG molecule for increased half-life |
| CA2249195A1 (en) | 1996-03-18 | 1997-09-25 | Board Of Regents, The University Of Texas System | Immunoglobin-like domains with increased half lives |
| DE60226702D1 (de) * | 2001-02-16 | 2008-07-03 | Conjuchem Biotechnologies Inc | Lang wirkendes glucagon-ähnliches peptid-2 für die behandlung von gastrointestinalen krankheiten und störungen |
| US20090238838A1 (en) * | 2003-11-13 | 2009-09-24 | Hanmi Pharm. Ind. Co. Ltd. | Insulinotropic peptide conjugate using an immunoglobulin fc |
| DE602005022239D1 (de) * | 2004-04-23 | 2010-08-19 | Conjuchem Biotechnologies Inc | Festphase zur Verwendung in einem Verfahren zur Reinigung von Albuminkonjugaten |
| KR101200227B1 (ko) * | 2005-05-04 | 2012-11-13 | 질랜드 파마 에이/에스 | 글루카곤 유사 펩티드-2(ｇｌｐ-2) 유사체 |
| JP2008169195A (ja) * | 2007-01-05 | 2008-07-24 | Hanmi Pharmaceutical Co Ltd | キャリア物質を用いたインスリン分泌ペプチド薬物結合体 |
| WO2010042145A1 (en) * | 2008-09-19 | 2010-04-15 | Nektar Therapeutics | Polymer conjugates of glp-2-like peptides |
| KR101746686B1 (ko) * | 2010-10-26 | 2017-06-15 | 한미사이언스 주식회사 | 면역글로불린 단편을 이용한 글루카곤 유사 펩타이드―２（ｇｌｐ―２）약물 결합체 |
| EP2755675B1 (en) * | 2011-09-12 | 2018-06-06 | Amunix Operating Inc. | Glucagon-like peptide-2 compositions and methods of making and using same |
| KR101895047B1 (ko) * | 2011-12-30 | 2018-09-06 | 한미사이언스 주식회사 | 면역글로불린 단편을 이용한 위치 특이적 글루카곤 유사 펩타이드-2 약물 결합체 |
-
2018
- 2018-09-28 BR BR112020006189-1A patent/BR112020006189A2/pt unknown
- 2018-09-28 EP EP18860379.9A patent/EP3689898A4/en active Pending
- 2018-09-28 WO PCT/KR2018/011586 patent/WO2019066586A1/ko active Application Filing
- 2018-09-28 TW TW107134398A patent/TWI795443B/zh active
- 2018-09-28 CN CN201880074180.4A patent/CN111433221A/zh active Pending
- 2018-09-28 CA CA3084326A patent/CA3084326A1/en active Pending
- 2018-09-28 SG SG11202002563WA patent/SG11202002563WA/en unknown
- 2018-09-28 AU AU2018339210A patent/AU2018339210B2/en active Active
- 2018-09-28 MX MX2020004453A patent/MX2020004453A/es unknown
- 2018-09-28 JP JP2020517828A patent/JP2020534840A/ja active Pending
- 2018-09-28 EA EA202090571A patent/EA202090571A1/ru unknown
- 2018-09-28 TW TW110126453A patent/TWI794897B/zh active
- 2018-09-28 AR ARP180102806A patent/AR113258A1/es unknown
-
2020
- 2020-03-19 PH PH12020550105A patent/PH12020550105A1/en unknown
- 2020-03-23 IL IL273528A patent/IL273528A/en unknown
- 2020-03-24 ZA ZA2020/01888A patent/ZA202001888B/en unknown
- 2020-03-27 US US16/832,634 patent/US11530249B2/en active Active
-
2022
- 2022-04-14 US US17/721,048 patent/US20220251164A1/en active Pending
- 2022-11-02 US US17/979,531 patent/US20230090790A1/en active Pending
-
2023
- 2023-07-06 JP JP2023111438A patent/JP2023138505A/ja active Pending
Also Published As
| Publication number | Publication date |
|---|---|
| TW201927806A (zh) | 2019-07-16 |
| JP2020534840A (ja) | 2020-12-03 |
| US20220251164A1 (en) | 2022-08-11 |
| AU2018339210B2 (en) | 2023-02-02 |
| PH12020550105A1 (en) | 2020-12-07 |
| CN111433221A (zh) | 2020-07-17 |
| AU2018339210A1 (en) | 2020-04-16 |
| MX2020004453A (es) | 2020-07-24 |
| US20230090790A1 (en) | 2023-03-23 |
| TW202142560A (zh) | 2021-11-16 |
| ZA202001888B (en) | 2021-05-26 |
| EA202090571A1 (ru) | 2020-07-30 |
| EP3689898A1 (en) | 2020-08-05 |
| CA3084326A1 (en) | 2019-04-04 |
| KR20190037181A (ko) | 2019-04-05 |
| US20200262888A1 (en) | 2020-08-20 |
| WO2019066586A1 (ko) | 2019-04-04 |
| IL273528A (en) | 2020-05-31 |
| TWI795443B (zh) | 2023-03-11 |
| KR20240013836A (ko) | 2024-01-30 |
| SG11202002563WA (en) | 2020-04-29 |
| BR112020006189A2 (pt) | 2020-10-13 |
| TWI794897B (zh) | 2023-03-01 |
| JP2023138505A (ja) | 2023-10-02 |
| US11530249B2 (en) | 2022-12-20 |
| EP3689898A4 (en) | 2021-06-16 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| AR113258A1 (es) | Conjugados persistentes de derivados del péptido 2 similar al glucagón (glp-2) | |
| HRP20240016T1 (hr) | Konjugati polipeptida interleukina-2 i njihove uporabe | |
| AR121587A2 (es) | Nuevos péptidos y nueva combinación de péptidos para el uso en la inmunoterapia contra el cáncer de páncreas y otros tipos de cáncer | |
| CO2018008763A2 (es) | Péptidos, combinaciones de péptidos y células para el uso en la inmunoterapia contra el cáncer de vejiga urinaria y otros tipos de cáncer | |
| CL2021000901A1 (es) | Enlazadores de conjugación que contienen el grupo 2,3-diaminosuccinilo | |
| CL2018000780A1 (es) | Péptidos y combinación de péptidos para el uso en la inmunoterapia contra el cáncer microcítico de pulmón y otros tipos de cáncer | |
| MD3322717T2 (ro) | Noi peptide și combinație de peptide pentru utilizare în imunoterapie împotriva cancerului ovarian epitelial și a altor cancere | |
| AR115516A2 (es) | Formulación de acción prolongada de la hormona estimuladora de los folículos humana, métodos para prepararla y conjugado de dicha hormona | |
| AR086660A1 (es) | Composicion para el tratamiento de diabetes que comprende un conjugado de insulina de accion prolongada y conjugado de un peptido insulinotropico de accion prolongada | |
| CR20180051A (es) | Nuevos epítopos celulares y nuevas combinaciones de epítopos celulares para el uso en la inmunoterapia del mieloma y de otros tipos de cáncer. | |
| CR20180245A (es) | Nuevos péptidos y combinación de péptidos para el uso en la inmunoterapia contra varios tipos de cáncer | |
| PE20221909A1 (es) | Moleculas de union a antigeno que comprenden un trimero de ligando de la familia de tnf | |
| CL2020002387A1 (es) | Péptidos (seq id no: 39) y combinación de péptidos de origen no canónico para el uso en la inmunoterapia contra diferentes tipos de cáncer (divisional de la solicitud no. 202002123) | |
| BRPI0309868B8 (pt) | métodos de preparação de uma composição de reduzida fração conjugada inferior | |
| CL2013003634A1 (es) | Complejo que comprende una proteina de fusion que comprende, un peptido viral, peptido conector, microglobulina beta 2 , peptido conector, dominios extracelulares alfa 1, 2 y 3 de mhc de clase i y un tercer peptido conector; metodo de produccion; formulacion farmaceutica que lo comprende; y su uso | |
| JP2012509902A5 (es) | ||
| GEP20074016B (en) | Polymer conjugates with decreased antigenicity, methods of preparation and uses thereof | |
| NO20062687L (no) | Immunogene peptidbaererkonjugater og fremgangsmater for fremstilling av samme | |
| NZ630888A (en) | Antibody drug conjugate (adc) purification | |
| JP2014506135A5 (es) | ||
| MD3319985T2 (ro) | Noi peptide și combinații de peptide pentru utilizare în imunoterapie împotriva cancerului esofagian și a altor cancere | |
| CR20180040A (es) | Nuevos péptidos y nuevas combinaciones de péptidos para el uso en la inmunoterapia y métodos para crear soportes para el uso contra el cáncer de páncreas y otros tipo de cáncer. | |
| CR20180591A (es) | Nuevos péptidos y nueva combinación de péptidos como dianas y para el uso en la inmunoterapia contra el cáncer de vesícula biliar y el colangiocarcinoma, así como otros tipos de cáncer | |
| RU2018120696A (ru) | Конъюгаты анти-cd22 антитело-майтансин и способы их применения | |
| CL2020002949A1 (es) | Péptidos y combinaciones de péptidos para el uso en la inmunoterapia contra la leucemia y otros tipos de cáncer (divisional de la solicitud 201902878) |